Tagrix (Osimertinib) 80 MG – 30 Tablets

Description

Tagrix  (Osimertinib ) is the #1st and only drug of its kind approved by USFDA for the treatment of epidermal growth factor receptor (EGFR) positive Non- Small Cell Lung Cancer (NSCLC) patient with T790M mutation.

 

Product Features:

Product Name	: Tagrix
Generic Name	: Osimertinib
Manufacturer	: Beacon Pharma Ltd
Indication	: Non- Small Cell Lung Cancer
Formulation	: Tablet
Strength	: 80 mg
Quantity	: 30 Tablets
Storage	: Room temperature
Registrations	: Export Only

Tagrix 80 mg Price: $310.00

 

Tagrix 80 mg Tablets manufactured by Beacon consists of generic molecule which is use for the treatment of lung cancer. This molecule is marketed by Beacon with the brand name Tagrix 80 mg. Consumer needs to provide a prescription copy to buy anti-cancer & other medicines from Glareamed.

 

Therapeutic Indications 

This product indicate for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

 

Indications Of  Tagrix 80mg Tablet

Tagrix indicate for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) and detected by an FDA-approved test. This disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

• Take according to the doctor’s advice
• Therapeutic Class
• Cytotoxic Chemotherapy

 

Pharmacology

This generic product is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion). This drug predominate in non-small cell lung cancer (NSCLC). Tumours follow the treatment with first-line EGFR-TKIs. As a third-generation tyrosine kinase inhibitor, this is specific for the gate-keeper T790M mutation. The Medicine increases ATP binding activity to EGFR and results in poor prognosis for late-stage disease.  The Capsule spare wild-type EGFR during the therapy. After reducing non-specific binding and limiting toxicity.

 

Tagrix 80 mg Dosage:

The recommended dose of Capsule once a day until disease progression or unacceptable toxicity. This medicine can taken with or without food.

👉 Take according to the doctor’s advice 🩺

 

Interaction

If concurrent use is unavoidable, increase with dosage to 160 mg daily. Process with a strong CYP3A inducer by coadministering . Resume at 80 mg 3 weeks after discontinuation of the strong CYP3A4 inducer.

 

 Tagrix 80 MG  Side Effects

The side effects of Tagrix 80 Mg tablets are Interstitial Lung Disease or Pneumonitis, QTc Interval Prolongation, Cardiomyopathy, Keratitis

Other common side effects of Tagrix 80 mg include:
• Diarrhea
• Rash
• Fatigue
• Decreased appetite
• Mouth sores
• Dry skin
• Nail problems
• Low blood cell counts
• Risk of infection

 

Tagrix vs Tagrisso

Tagrix and Tagrisso are both medications containing the same active ingredient: osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) used primarily to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations (such as exon 19 deletions, L858R, or T790M).

Key Similarities

Active ingredient and mechanism: 

Both drugs are osimertinib. They work by irreversibly blocking mutated EGFR proteins on cancer cells, inhibiting tumor growth and spread. This includes activity against the T790M resistance mutation that often develops after first-generation EGFR TKIs (like erlotinib or gefitinib).

 

Indications – They are used for:

• Advanced/metastatic EGFR-mutated NSCLC (first-line or after progression on earlier TKIs).
• Adjuvant therapy after surgery in early-stage EGFR-mutated NSCLC.
• Other approved settings like unresectable stage III NSCLC post-chemoradiation (based on evolving approvals for osimertinib).

 

Efficacy: 

Clinical data and patient reports show similar effectiveness. Many patient communities (e.g., on forums like CancerGRACE, Inspire, Reddit’s r/nsclc, and EGFR Resisters groups) report that Tagrix performs equivalently to Tagrisso in controlling disease, shrinking tumors, and extending progression-free survival. Some groups have independently tested pills and found the formulations chemically identical.

 

Side effects: 

Common ones include diarrhea, rash, dry skin, nail changes, fatigue, and musculoskeletal pain. More serious risks (e.g., interstitial lung disease, QT prolongation, cardiomyopathy) are the same since the active drug is identical.

 

Key Differences

 

Aspect	Tagrisso	Tagrix
Manufacturer	AstraZeneca (branded/original)	Beacon Pharmaceuticals (Bangladesh)
Status	Globally patented and FDA/EMA-approved	Generic version (first global generic of osimertinib, approved in Bangladesh; not FDA-approved in the US but widely used in regions with patent differences
Availability	Widely available in US, Europe, etc. (prescription, often with patient assistance programs)	Primarily in Asia, Middle East, and select markets; often accessed via import in high-cost regions
Cost	Very expensive (e.g., ~$15,000–$18,000+ USD for 30 tablets/80 mg in the US without assistance)	Significantly cheaper (often $300–$500 for 30 tablets/80 mg, or even lower in Bangladesh; ~70–90% less than branded)
Regulatory	Full global approvals with extensive clinical trials (e.g., FLAURA, ADAURA, LAURA studies)	Relies on bioequivalence to original; accepted as equivalent by many oncologists and patients in practice

 

Practical Considerations

In countries like the US, Canada, or Europe, Tagrisso is the standard prescribed version due to regulatory approval and patent protection. Tagrix is not officially available there. However, We, EmergencyDrug.com, supply Tagrix with a valid preciption through DHL & EMS courier service. For more info, please contact us via whatsapp.

In regions with high drug costs (e.g., USA, UK, Australia, Canada, Ireland, parts of the Middle East), many patients switch to Tagrix (or similar generics like Osicent or Osimert) for affordability, with numerous anecdotal reports of good responses, stable disease, or tumor shrinkage.

Always consult an oncologist before switching or starting any version –  they can guide on testing for EGFR mutations, monitoring, and whether a generic is appropriate in your location. Patient assistance programs exist for Tagrisso in many countries to reduce costs.

In summary, Tagrix is essentially a generic equivalent to Tagrisso – the same drug at a much lower price, and is widely regarded as comparable in effectiveness by patients and some clinicians, though the branded version has broader formal regulatory backing in high-income countries.

 

Osimertinib 80 mg buy online: $310.00 

 

Our Shipping Countries:

United States, Canada, Mexico, Brazil, Argentina, United Kingdom, France, Germany, Italy, Spain, Portugal, Netherlands, Belgium, Switzerland, Austria, Sweden, Norway, Denmark, Finland, Iceland, Russia, China, Japan, South Korea, North Korea, Vietnam, Thailand, Malaysia, Singapore, Indonesia, Philippines, Australia, New Zealand, South Africa, Egypt, Nigeria, Kenya, Ethiopia, Morocco, Turkey, Saudi Arabia, United Arab Emirates, Iran, Iraq, Syria, Lebanon, Jordan, Qatar, Bahrain, Kuwait, Oman, Yemen, Afghanistan, Sri Lanka, Nepal, Bhutan, Maldives.

Myanmar, Cambodia, Laos, Mongolia, Kazakhstan, Uzbekistan, Turkmenistan, Kyrgyzstan, Tajikistan, Azerbaijan, Armenia, Georgia, Ukraine, Belarus, Poland, Czech Republic, Slovakia, Hungary, Romania, Bulgaria, Greece, Albania, Serbia, Montenegro, Bosnia and Herzegovina, Croatia, Slovenia, North Macedonia, Kosovo, Malta, Cyprus, Tunisia, Algeria, Libya, Sudan, Sierra Leone, Liberia, Ivory Coast, Ghana, Uganda, Zambia, Malawi, Zimbabwe, Namibia, Angola, Somalia, Eritrea, Etc.

 

Visit our another cancer related product here